The Role of Breath Testing in Enriching the Likelihood of Response to Rifaximin in Patients With Diarrhea IBS

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03729271

Title field or adapter rule

{'original_value': 'The Role of Breath Testing in Enriching the Likelihood of Response to Rifaximin in Patients With Diarrhea IBS', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:35.554795+00:00

Published At

2026-01-12T00:00:00+00:00

Record Updated At

2026-01-12

Source Retrieved At

2026-10-31T22:18:52.668840+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Irritable Bowel Syndrome", "Irritable Bowel Syndrome With Diarrhea"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-01-12", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT03729271"

protocolSection.identificationModule.officialTitle

"The Role of Breath Testing in Enriching the Likelihood of Response to Rifaximin in Patients With Diarrhea IBS"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE4"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Irritable Bowel Syndrome (protocolSection.conditionsModule.conditions)
• Irritable Bowel Syndrome With Diarrhea (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Rifaximin and breath tests'], 'description': 'Rifaximin will be given during weeks 2-4', 'name': 'Rifaximin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Rifaximin and breath tests'], 'description': 'Subjects will undergo glucose and lactulose hydrogen breath tests for Small Intestinal Bacterial Overgrowth (SIBO) on consecutive days using a commercially available home base kits (Glucose Hydrogen Breath Test Collection Kit and Lactulose Hydrogen Breath Test Collection Kit for SIBO from Commonwealth Diagnostic International) prior to Rifaximin treatment and at week 13 of the study.', 'name': 'Glucose and lactulose hydrogen breath testing', 'type': 'DEVICE'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Rifaximin (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.